For engineering teams developing products, processes, or technical improvements, understanding patent claim boundaries is part of managing intellectual property risk. The UK Supreme Court’s 2017 decision in Actavis v Lilly changed how infringement is assessed by separating the ordinary interpretation of a patent claim from the question of whether a variant may still infringe as an equivalent. The patent doctrine of equivalents therefore matters to technical decision-makers assessing design alternatives and freedom to operate.
Why patent claim scope matters to technical teams
A patent grants its owner a defined legal monopoly. Its claims set out the protected invention, while the description and drawings help explain those claims. For a manufacturer or system integrator, the practical issue is whether a proposed product or process falls within that protected scope—and whether a licence or a different design approach may be needed.
Patent claims are not always applied as a simple checklist of words. Their meaning is considered in context, including how a person skilled in the relevant field would understand them. That makes claim interpretation an important consideration when a design changes a component, material, method, or operating principle but retains much of the patented invention’s function.
Before Actavis, the UK approach associated with Kirin-Amgen focused infringement analysis on what the skilled person understood the claim language to mean. The Supreme Court found that this approach had combined two distinct questions: interpreting the claim and determining the extent of protection. The ruling introduced a two-stage analysis.
The two stages of the Actavis infringement test
The court first asks whether the alleged variant infringes under the claim’s normal interpretation. This is a contextual reading of the claim, not necessarily a rigid, word-for-word exercise. If the variant falls within the claim as interpreted, the analysis can end there.
If it does not, the court asks whether the variant nevertheless infringes because its differences from the claimed invention are immaterial. In Actavis, the Supreme Court adapted the established “Improver” questions to help assess this issue. The questions focus on the technical relationship between the variant and the invention, and on whether the patent indicates that strict compliance with the claim wording is essential.
Questions that guide the equivalents analysis
- Result and method: Does the variant achieve substantially the same result, in substantially the same way, as the invention’s inventive concept?
- Knowledge of the skilled person: Would it have been obvious to a skilled person, reading the patent at its priority date and knowing that the variant achieves substantially the same result, that it does so in substantially the same way?
- Essentiality: Would the skilled reader understand that the patentee intended strict compliance with the literal meaning of the claim to be essential?
These questions are not a substitute for examining the patent and the technical facts. Their answers depend on the particular claim, specification, invention, and variant at issue.
What the Actavis case demonstrates
The dispute concerned a patent for the use of pemetrexed disodium with vitamin B12. Actavis proposed medicines using other pemetrexed forms. The Supreme Court accepted that these products did not infringe on a normal interpretation of the claim, but held that they were immaterial variants and infringed under the equivalents analysis.
The decision illustrates why a change in a specified element does not automatically settle the infringement question. The court considered whether the alternatives worked in substantially the same way and whether the patent suggested that the named form was intended to be an essential boundary. For product developers, the broader point is that technical differences need to be assessed in relation to the invention as a whole, not just by comparing labels or isolated claim terms.
Implications for design changes and freedom to operate
The doctrine can affect early design reviews, patent clearances, and litigation strategy. A variant that appears to sit outside the ordinary meaning of a claim may still attract an infringement argument. Conversely, not every functionally similar alternative will qualify as an equivalent: the analysis depends on the relevant technical evidence and the patent’s teaching.
Engineering and product teams can support a more useful assessment by documenting:
- Which elements of a proposed design differ from the patent claims.
- How those changes affect the technical operation and result of the product or process.
- Whether the specification identifies the relevant feature as central or describes alternatives.
- When the variant was developed and what technical knowledge was available at the patent’s priority date.
This information does not itself determine infringement, but it can help patent counsel evaluate claim scope and the potential relevance of equivalents. The ruling also noted that expert evidence may play an important role in assessing technical questions. In some cases, parties may be asked to explain precisely what result and method they say are shared between the patented invention and the alleged variant.
Equivalents are not the same as claim interpretation
After Actavis, UK courts discussed whether “normal interpretation” should be understood as purposive interpretation rather than a literal reading. In decisions described in the period following the ruling, courts continued to apply purposive construction at the first stage. The two-stage structure nevertheless matters: ordinary claim interpretation and the additional equivalents inquiry are separate parts of the infringement analysis.
The decision also raised questions about how infringement by equivalence relates to patent validity, including novelty and the traditional infringement-versus-anticipation “squeeze.” The commentary on the ruling identified these issues as matters requiring further judicial consideration. They should not be treated as settled simply because the infringement test now includes an equivalents stage.
Practical takeaway
For industrial businesses, Actavis v Lilly is a reminder that patent risk cannot always be assessed by checking whether a design reproduces the exact words of a claim. Teams evaluating a product change should consider both normal claim interpretation and whether the difference could be viewed as immaterial in light of the invention’s technical concept. Early coordination between engineering, product, and IP specialists can help clarify those questions and inform design and licensing decisions. Because the outcome turns on the specific patent and facts, a qualified patent professional should assess any concrete freedom-to-operate concern.